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Results: Dose of busulfan was adjusted in 25 patients (54%). 
Through levels 25 to 1244 ng/mL, peak levels 849–4586 ng/mL 
bearing AUC 2225 ng/mL.h–12,818 ng/mL.h were observed. The 
median total dose of infused drug was 17.52 mg/kg (10.7–22.9). 
All patients have engrafted, 33 (94%) patients after allogeneic 
HSCT have reached complete donor chimerism. Acute graft versus 
host disease grade III-IV manifested in 6 (17%), mucositis grade 
III-IV was seen in 28 (61%), and VOD was diagnosed in 8 (17%) 
patients. Defibrotide was administered in 15 patients (therapeuti-
cally in 9, as prophylaxis in 8). Neurotoxicity was documented 
in 2 patients. Relapse occurred in 6 (13 %) patients; 10 (22%) 
patients died, 5 due to toxicity before day 100 after HSTC, 1 child 
15 months after HSCT, 4 due to relapse. 32 children are alive/
well (70%).
Conclusion: Parenteral busulfan was used in full myeloablative dose 
and in combination with other drugs; therefore, toxicity rather than 
underexposure was our main concern. However, clear correlation 
between AUC and toxicity was not observed. Because of interindivid-
ual differences and changes in pharmacokinetics during the busulfan 
course, we strongly recommend intensive TDM.
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Introduction: Angiogenesis inhibitors have remarkably improved the 
outcome of patients with several types of cancer. One of the most 
reported side effects of angiogenesis inhibitors is hypertension. In a 
previous study, we showed that infusion of bevacizumab, an antibody 
directed against vascular endothelial growth factor (VEGF), acutely 
decreased endothelium-dependent vasodilation in healthy volunteers 
(A. Thijs et al Hypertension 2013;Epub ahead of print). Sunitinib, 
an inhibitor of tyrosine kinases including the VEGF-receptor, causes 
cardiovascular side effects similar to bevacizumab. We expected that 
antagonism of the VEGF receptor and subsequent endothelial dys-
function mediates these cardiovascular adverse events of sunitinib. 
Therefore, we hypothesized that sunitinib reduces endothelium-
dependent vasodilation before hypertension.
Patients (or Materials) and Methods: In patients with metastatic 
renal cell carcinoma before and 1 week after start of clinically 
indicated sunitinib (50 mg/d) the endothelium-dependent vasodi-
lator response to intra-arterial acetycholine (ACH, 0.5, 2.0, and 
8.0 µg/dL forearm volume/min) and the endothelium-independent 
vasodilator response to intra-arterial sodium nitroprusside (SNP, 
0.06, 0.2, and 0.6 µg/dL forearm volume/min) were assessed with 
venous occlusion plethysmography. Moreover, blood pressure was 
measured in supine position at the end of each experiment. For 
statistical analyses, the FBF ratio (FBF in experimental arm/FBF in 
control arm) was logarithmically transformed to obtain a Gaussian 
distribution. Results are expressed as percentage response from 
baseline (mean [SEM]).
Results: Ten male patients with a mean age of 55 years (range, 
24–68 years) were included. No significant changes in FBFresponses 
before and after start of sunitinib were observed (Table). Blood 
pressure (MAP) before was 101.9 (3.8) mm Hg and 106.1 (2.6) 
mm Hg after 1 week of treatment (not significant). After 2 weeks 
of treatment, the blood pressure had increased to 115.8 (4.9) mm 
Hg (P < 0.05).
Conclusion: One-week treatment with sunitinib did not specifically 
affect endothelium-dependent vasodilation before the development 
of hypertension.These observations indicate that bevacizumab and 
sunitinib differ with respect to their vascular actions in humans in 
vivo and suggest that other factors contribute to the development of 
hypertension in response to sunitinib rather than endothelial dys-
function.
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Introduction: Pancreatic cancer patients have an overall 5-year sur-
vival of < 5% worldwide, due to both late-stage diagnosis and lack of 
treatment options. Therefore, the development of novel chemothera-
peutic modalities based on a deeper understanding of the disease is 
essential for improving patient survival. We have recently developed 
Minnelide, a novel prodrug of the diterpene triepoxide, triptolide, as 
a novel chemotherapy against pancreatic cancer. Although Minnelide 
has shown great promise in preclinical studies using various animal 
models of pancreatic cancer, its mechanism of action remains unclear. 
NFkB activity and HSP70 expression are pro-survival pathways up-
regulated in pancreatic cancer. Previous studies from our group and 
others have shown that triptolide decreases NFkB activity. We have 
also shown that triptolide-mediated loss of HSP70 results in pancre-
atic cancer cell death. However, it is unclear if down-regulation of 
both HSP70 and NFkB are part of sequential or parallel pathways. 
We hypothesized that a triptolide-mediated decrease in NFkB activity 
results in down-regulation of HSPs, resulting in cell death.
Patients (or Materials) and Methods: Tumor volume evaluation: 
5 × 105 MIA PaCa-2, S2-VP10, S2-013, AsPC-1, or KPC (derived 
from KRasG12D; Tp53R172H; Pdx-1 Cre animals) pancreatic can-
cer cells were injected subcutaneously into animals and tumor volume 
measured 28 days postinoculation. RNA and Protein: RNA levels 
were assessed using real-time qPCR. Protein levels were evaluated by 
western blotting. NFkB activity: NFkB activity was measured using 
a p50 binding assay kit (Pierce).
Results: Using either KPC cell lines, known to mimic human pan-
creatic cancer progression, or human tumors, we show that the KPC 
cell line is the most aggressive of all cell lines tested in its ability to 
form tumors. The KPC cell line also possesses the highest NFkB activ-
ity of all cell lines tested, accentuating the importance of NFkB in 
pancreatic cancer. To evaluate the mechanism of action of Minnelide, 
we used 2 human tumor-derived pancreatic cancer cell lines: MIA 
PaCa-2, derived from a primary tumor, and S2-VP10, derived from 
a liver metastasis. In both of these cell lines, triptolide treatment 
decreases RNA and protein levels of p50 and p65, as well as NFkB 
Table. FBF ratio (% increase from baseline)
ACH 0.05 ACH 2.0 ACH 8.0 SNP 0.06 SNP 0.2 SNP 0.6
Before 
sunitinib
246 (100) 1098 
(765)
1412 
(737)
692 (357) 1184 
(552)
3703 
(2320)
After 
sunitinib
201 (76) 252 (72) 542 (144) 378 (158) 1078 
(614)
1746 
(665)
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activity. Importantly, inhibition of NFkB with Bay 11-7085 (8.5 
mM) leads to loss of cell viability and is accompanied by decreased 
levels of HSP70 and HSP27, as well as their transcription factor, 
HSF-1, at the RNA and protein levels. Furthermore, overexpression 
of a phosphorylation-deficient mutant of IKBa in MIAPaCa-2 cells 
resulted in decreased NFkB activity and the loss of HSP70 expression.
Conclusion: HSP70 is known to be regulated by several mechanisms. 
Here we show a novel NFkB-mediated mechanism by which HSF-1 
and its transcriptional targets, HSP27 and HSP70 are down-regulated 
in pancreatic cancer cells in response to triptolide.
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Introduction: Although the oxidative stress and inflammation are 
closely related with breast cancer, there is no study directly examining 
the possible changes in vascular functions in the presence of breast 
carcinoma. The goal of the present study was to evaluate changes in 
vascular reactivity in tumor-bearing mice.
Patients (or Materials) and Methods: In this study, highly metastatic 
breast carcinoma cells which was derived from liver or brain metasta-
sis of 4T1 murine breast carcinoma (4TLM and 4TBM, respectively), 
and 67NR cells which is tumorogenic but nonmetastatic cells were 
used. Female Balb-c mice 8 to 10 weeks old were divided into fol-
lowing groups: (1) control; (2) injected with 67NR; (3) injected with 
4TLM; and (4) injected with 4TBM orthotopically. Thoracic aorta 
was removed 25 days after injection of tumor cells. Isometric tension 
studies were performed in response to potassium chloride (KCl), 
phenylephrine (Phe), acetylcholine (ACh, an endothelium-depend-
ent vasodilator), and sodium nitroprusside (SNP, an endothelium-
independent vasodilator). Endothelial nitric oxide synthase (eNOS), 
phosphorylated eNOS (Ser 1177) (p-eNOS), gp91phox, and tumor 
necrosis factor-α (TNF-α ) expressions in aortic tissues were demon-
strated by immunohistochemistry. The level of TNF-α in vascular 
tissue was evaluated by ELISA.
Results: Presence of tumor was resulted in significant inhibition of 
response to ACh in both 4TLM- and 4TBM-injected mice but not 
67NR-injected mice. Furthermore, both KCl and Phe-induced con-
traction of thoracic aorta was not changed significantly in tumor-
bearing animals. eNOS and p-eNOS expressions decreased while 
gp91phox and TNF-α expressions increased in endothelium sig-
nificantly in mice with metastatic breast carcinoma compared with 
67NR-injected and control mice. Moreover, TNF-α levels of thoracic 
aorta in 4TLM and 4TBM mice were higher than that of 67NR mice. 
Tumor-induced endothelial dysfunction determined by ACh-induced 
relaxation improved by superoxide dismutase (SOD), apocynin (a 
NADPH oxidase inhibitor), and infliximab (a TNF-α monoclonal 
antibody).
Conclusion: The findings of this study suggest that presence of 
metastatic breast carcinoma may cause a significant reduction in 
endothelium-dependent relaxation of thoracic aorta via NADPH 
oxidase-mediated oxidative stress and TNF-α production.
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Introduction: Cyclin D1 is required for cells to progress from the 
G1 phase of the cell cycle into the S phase. Mutation or overexpres-
sion of cyclin D1, often occurring in tumors, leads to uncontrolled 
cell cycle progression and proliferation. QTRRE (rodent) as well 
as ACHN and 786-O (human) cell models of renal cell carcinoma 
(RCC) display elevated cyclin D1 protein levels. Pentoxifylline (PTX), 
an FDA-approved competitive, nonspecific phosphodiesterase inhibi-
tor, has found recent use as an adjunct in chemotherapy for patients 
to help treat cachexia and capillary leak syndrome.
Patients (or Materials) and Methods: We utilized Western blot analy-
sis as well as propidium iodide-based cell cycle analysis to study the 
effects of PTX in our RCC cell models.
Results: Initially (0–8 hours), PTX induced a time- and dose- 
(35 µM–3.5 mM) dependent decrease in cyclin D1 levels in the RCC 
cell models. Cotreatment with PTX and the protein translation 
inhibitor, cycloheximide (5–25 µM), revealed a decrease in cyclin 
D1 protein half-life. Furthermore, the PTX-induced decrease of cyclin 
D1 was abolished in the presence of a proteasome inhibitor (MG-
132, 10 µM) in all 3 RCC cell models. Subsequently (12–72 hours), 
PTX caused maximal cyclin D1 decreases in QTRRE and ACHN 
cells, whereas cyclin D1 levels in 786-O cells recovered and surpassed 
initial amounts seen in the control. Concomitant with cyclin D1 lev-
els, QTRRE and ACHN cells demonstrated enhanced G1 phase cell 
cycle arrest at 24 hours (170% and 140%, respectively) compared 
with 786-O cells (107%) and the nontumorigenic human kidney cell 
line HK-2 (107%).
Conclusion: The data suggest that PTX decreases cyclin D1 protein 
levels by stimulating proteasomal degradation (and subsequent G1 
phase arrest), which is sustained in the QTRRE and ACHN but not 
786-O RCC cell models. The data reveal a need to better under-
stand the differences in PTX response between the RCC cell models. 
Moreover, an ability to predict a positive response to PTX may con-
tribute to better personalized cancer therapy treatment for patients. 
Because our findings also reveal a novel anticancer chemotherapeutic 
property of PTX, the utility of PTX as an adjuvant therapy in the 
treatment of cancer should be further explored.
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Introduction: Photodynamic therapy (PDT) is an anticancer treat-
ment that uses light to activate cytotoxic compounds killing cancer 
cells. Sonodynamic therapy (SDT) is a new anticancer treatment 
where ultrasound is used to trigger the cytotoxic effect of chemical 
compounds known as sonosensitizers. SDT is able to focus the ultra-
sound energy, generated by selected continuous or pulsed ultrasound 
such as shock waves (SW), onto malignant sites situated deeply inside 
tissues overcoming the main drawback linked to the use of PDT: the 
poor penetration of light in biological tissues. Even if the SDT mecha-
nism is still under debate, some researchers suggest a common basic 
